[Keratoacanthoma centrifugum marginatum].
BACKGROUND
Keratoacanthoma centrifugum marginatum (KCM) is a rare keratoacanthoma. Treatment relies essentially on exeresis which is however difficult due to the widespread nature of the lesions.


METHODS
A patient with a 1 year history of KCM associated with psoriasis vulgaris was successfully treated with etretinate (1 mg/kg/day) for 5 months. This medical therapy made it possible to avoid the classical surgery and to blanch the associated psoriasis.


CONCLUSIONS
Several authors have shown the favourable effect of etretinate on multiple or large single-site keratoacanthomas. To our knowledge, this is the first case reported of successful treatment with etretinate in a case of keratoacanthoma associated with psoriasis. We suggest that this drug could be an effective alternative to mutilating surgery for this specific variety of keratoacanthoma.
Chaffai
M
M
Polyclinique Ettaoufki, Hôpital La Rabta, Tunis.
Houman
M H
MH
Haouet
S
S
Ben Osman
A
A
D000368:Aged; D000369:Aged, 80 and over; D005050:Etretinate / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007636:Keratoacanthoma / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D007868:Leg Dermatoses / Q000188:drug therapy / Q000209:etiology*; D011565:Psoriasis / Q000150:complications; D016896:Treatment Outcome
D005050:Etretinate
Kératoacanthome centrifuge marginé.